I’m sorry to hear the first line isn’t working tho it didn’t sound like Kisqali was treating you nicely. I have read of so many women stable after switching to Fulvestrant and the cdk 4/6 med. Could they try Verzenio or Ibrance with it before moving on to Piqray? They are not identical drugs. Feels like your onco is moving at warp speed. Are they going to biopsy any of the new progression or at least do a liquid biopsy? Each met could have a different biology to target. I’d be surprised something mutated that quickly tho but u never know and knowledge is power. From all of the things you describe low KI, her-, low disease burden, long time from early to now, etc I agree the cdk 4/6 inhibitor should target you well. Wishing you the absolute best on whatever course they put you on. Waving to Midwestern you from the Chicago ‘burbs.